{"id":35677,"date":"2026-01-30T18:45:50","date_gmt":"2026-01-30T18:45:50","guid":{"rendered":"https:\/\/cincinnatirighttolife.org\/?p=35677"},"modified":"2026-01-30T18:45:51","modified_gmt":"2026-01-30T18:45:51","slug":"trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks","status":"publish","type":"post","link":"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/","title":{"rendered":"Trump FDA seeks pause on abortion pill lawsuit while it reviews drug&#8217;s risks"},"content":{"rendered":"\n<p style=\"font-size:18px\"><strong><em>By:  Carole Novielli, originally published <a href=\"https:\/\/www.liveaction.org\/news\/trump-fda-seeks-pause-abortion-pill-lawsuit\" target=\"_blank\" rel=\"noreferrer noopener\">January 28, 2026, LiveAction.org<\/a><\/em><\/strong><\/p>\n\n\n\n<p class=\"has-medium-font-size\">he Food and Drug Administration (FDA) under the Trump administration has petitioned a federal court to&nbsp;<em>pause<\/em>&nbsp;the state of Louisiana&#8217;s abortion pill lawsuit, which is seeking a review of the 2023 safety regulations on the drug.<\/p>\n\n\n\n<p class=\"has-medium-font-size\">The troubling motion comes just days after President Donald Trump and Vice President J.D. Vance spoke to pro-lifers gathered in Washington, D.C., for the annual March for Life. Both men\u00a0<a href=\"https:\/\/www.liveaction.org\/news\/fact-check-supreme-court-abortion-pill-access\" target=\"_blank\" rel=\"noreferrer noopener\">previously<\/a>\u00a0stated they would not &#8220;block&#8221; the abortion pill, which has already ended the lives of over 7.5 million preborn babies since its original FDA approval just over 25 years ago.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Key Takeaways:<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">Trump&#8217;s FDA, which\u00a0<a href=\"https:\/\/www.liveaction.org\/news\/abortion-pill-generic-secrets-evita-solutions\" target=\"_blank\" rel=\"noreferrer noopener\">recently approved<\/a>\u00a0the second generic abortion pill, claimed Louisiana&#8217;s lawsuit seeking to put a &#8220;stay&#8221; on the 2023 REMS safety protocols (which allowed mail-order and pharmacy dispensing of the abortion pill) would &#8220;short circuit the [FDA]\u2019s orderly review and study of the safety risks of mifepristone.&#8221;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">The FDA asked the courts to &#8216;stay judicial review&#8217; until the FDA completes its own review of the drug, which it claims will be done in less than a year&#8217;s time.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">The Details:<\/h2>\n\n\n\n<p class=\"has-medium-font-size\">On January 27, 2026, the FDA&nbsp;<a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/storage.courtlistener.com\/recap\/gov.uscourts.lawd.213952\/gov.uscourts.lawd.213952.50.0_1.pdf\">petitioned the Court<\/a>&nbsp;to &#8220;stay all proceedings in this matter&#8221; while the agency &#8220;reviews the mifepristone Risk Evaluation and Mitigation Strategy.&#8221;<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"981\" height=\"747\" src=\"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/Court-Doc.jpg\" alt=\"\" class=\"wp-image-35678\" srcset=\"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/Court-Doc.jpg 981w, https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/Court-Doc-300x228.jpg 300w, https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/Court-Doc-768x585.jpg 768w\" sizes=\"auto, (max-width: 981px) 100vw, 981px\" \/><\/figure><\/div>\n\n\n<p class=\"has-medium-font-size\">The accompanying&nbsp;<a target=\"_blank\" rel=\"noreferrer noopener\" href=\"https:\/\/www.courtlistener.com\/docket\/71544002\/50\/1\/louisiana-v-u-s-food-drug-administration\/\">memorandum of law<\/a>&nbsp;reads in part:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-medium-font-size\">The Court should stay further litigation until after FDA\u2019s mifepristone REMS review is complete and deny Plaintiffs\u2019 motion without prejudice&#8230;.<\/p>\n\n\n\n<p class=\"has-medium-font-size\">The rationale for deferring judicial review is simple: the \u201charm of moving forward\u201d with judicial review of the 2023 REMS Modification outweighs the \u201charm of holding back.\u201d<\/p>\n\n\n\n<p class=\"has-medium-font-size\">&#8230; And the same calculus confirms that granting preliminary relief would not be equitable at this time because it would disrupt FDA\u2019s ongoing review.<\/p>\n<\/blockquote>\n\n\n\n<p class=\"has-medium-font-size\">In addition to a request that the Court &#8220;stay this case pending FDA\u2019s review,&#8221; the FDA&#8217;s motion asked that the Court &#8220;deny Plaintiffs\u2019 motion\u00a0<a href=\"https:\/\/legalclarity.org\/with-prejudice-vs-without-prejudice-key-legal-differences-explained\/\" target=\"_blank\" rel=\"noreferrer noopener\">without prejudice<\/a>.&#8221;<\/p>\n\n\n\n<p><\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><a href=\"https:\/\/x.com\/Washington_Rep\/status\/2016296756670054729\" target=\"_blank\" rel=\" noreferrer noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"714\" height=\"469\" src=\"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/x-post.jpg\" alt=\"\" class=\"wp-image-35679\" srcset=\"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/x-post.jpg 714w, https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/x-post-300x197.jpg 300w\" sizes=\"auto, (max-width: 714px) 100vw, 714px\" \/><\/a><\/figure><\/div>\n\n\n<h2 class=\"wp-block-heading\">The Backstory:<\/h2>\n\n\n\n<p class=\"has-medium-font-size\">Alliance Defending Freedom (ADF) filed the lawsuit,\u00a0<em>State of Louisiana v. FDA<\/em>,\u00a0<a href=\"https:\/\/www.liveaction.org\/news\/destructive-sovereignty-louisiana-mail-order-abortion-pill\" target=\"_blank\" rel=\"noreferrer noopener\">on behalf of<\/a>\u00a0the State of Louisiana and Rosalie Markezich, a woman whose &#8220;ex-boyfriend ordered mifepristone from a California doctor, received it by mail, and coerced Rosalie to take it, ending her baby\u2019s life.&#8221;<\/p>\n\n\n\n<p class=\"has-medium-font-size\">The Plaintiffs challenged the 2023 REMS safety regulations on the abortion pill as &#8220;unlawful&#8221; and are seeking to &#8220;restore the in-person dispensing requirement.&#8221;<\/p>\n\n\n\n<p class=\"has-medium-font-size\">The 2023 REMS essentially removed the in-person dispensing requirement for the drug, enabling the deadly abortion pill to be distributed by mail and in pharmacies. This created a &#8216;wild west&#8217; of sorts, in which pro-abortion states have begun to shield abortion providers who mail the drugs into pro-life states.<\/p>\n\n\n\n<p class=\"has-medium-font-size\">In addition, mail-order dispensing enabled incidents of coercion in which pregnant women were given the deadly pills without their knowledge or consent:<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"&quot;I felt pressured to take the pills&quot; | Rosalie&#039;s Story\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/PyC1_msah9U?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">FDA to &#8216;reconsider the restrictions on mifepristone&#8217;<\/h3>\n\n\n\n<p class=\"has-medium-font-size\">FDA is citing its own review of the abortion pill (mifepristone) as a reason for requesting the stay, calling &#8220;the validity of FDA\u2019s restrictions on mifepristone&#8221; a &#8220;hotly contested legal and scientific issue that has been the subject of litigation for many years&#8221;:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-medium-font-size\">Louisiana and Ms. Markezich are not the only plaintiffs to have challenged the current requirements for dispensing mifepristone. Indeed, five other states are challenging either the approval of mifepristone or subsequent actions easing restrictions&#8230;And aside from litigation, before the FDA are numerous citizen petitions\u2014citing voluminous material and seeking mutually inconsistent relief, such as suspending approval of the drug, restoring previous REMS requirements, or eliminating the REMS entirely.<\/p>\n\n\n\n<p class=\"has-medium-font-size\">Given this widespread debate over the safety of mifepristone, FDA has concluded that the best path forward is for the agency to reconsider the restrictions on mifepristone based on all the evidence before the agency. As noted above, that evidence will include FDA\u2019s own study. FDA has emphasized that it &#8216;is taking care to do this study properly and in the right way.<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\">FDA: Louisiana&#8217;s request to stay REMS would &#8220;short circuit&#8221; review<\/h3>\n\n\n\n<p class=\"has-medium-font-size\">At this time, \u201cFDA continues to work on the collection of the robust and timely data that is necessary for a well-controlled study with adequate statistical power,\u201d the FDA wrote:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-medium-font-size\">Although studies like these \u201coften take approximately a year or more to conduct,\u201d FDA\u2019s current plan is to complete the study \u201csooner than that timeframe.\u201d And once FDA has analyzed the data from that study (as well as all other evidence before the agency), it will decide whether \u201csubstantive changes to the REMS\u201d are necessary.<\/p>\n<\/blockquote>\n\n\n\n<p class=\"has-medium-font-size\">&#8220;Plaintiffs now threaten to short circuit the agency\u2019s orderly review and study of the safety risks of mifepristone by asking this Court for an immediate stay of the 2023 REMS Modification approved three years ago,&#8221; FDA claimed.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-medium-font-size\">They would have this Court set aside the 2023 REMS Modification\u2014all without the benefit of FDA\u2019s expertise, and even as the agency is already reconsidering the matter in its review. And Plaintiffs\u2019 requested relief may prove as unnecessary as it is disruptive, if FDA ultimately decides that the in person dispensing requirement must be restored.<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\">FDA: Defer judicial review until agency&#8217;s review is complete<\/h3>\n\n\n\n<p class=\"has-medium-font-size\">The FDA asked the court to defer judicial review until its review of mifepristone is complete, claiming that &#8220;awarding preliminary relief to these Plaintiffs could easily prompt other plaintiffs to seek a conflicting injunction that would sow administrative and judicial chaos.&#8221;<\/p>\n\n\n\n<p class=\"has-medium-font-size\">FDA went on to suggest that if the court hearings continue, it will &#8220;waste judicial resources.&#8221; They alleged that it would not be &#8220;far fetched&#8221; for a back-and-forth &#8220;disruption&#8221; in the courts, with one side getting relief and the other filing for conflicting relief.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-medium-font-size\">To prevent that disruption, the Court should exercise its inherent authority to stay this litigation pending the outcome of FDA\u2019s review of the mifepristone REMS. FDA\u2019s review will necessarily result in a new agency decision that could supersede the 2023 REMS Modification, obviating any need to consider the merits of Plaintiffs\u2019 arguments challenging the validity of the 2023 REMS Modification.<\/p>\n\n\n\n<p class=\"has-medium-font-size\">Any party adversely affected by the new agency decision on mifepristone may seek judicial review at that time. And in the event of a further REMS modification, adherence to FDA\u2019s normal process will create far less disruption than the abrupt, judicially imposed change sought by Plaintiffs.<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\">FDA: Plaintiffs lack standing to challenge 2023 REMS<\/h3>\n\n\n\n<p class=\"has-medium-font-size\">In its motion, the FDA claimed the Plaintiffs &#8220;lack standing&#8221; to challenge the 2023 REMS because these claims are &#8220;not traceable&#8221; to &#8220;defendant&#8221; (the FDA):<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-medium-font-size\">Louisiana suffers no sovereign injury because it remains free to make and enforce its pro-life policies after&nbsp;<em>Dobbs v. Jackson Women\u2019s Health Org<\/em>&#8230;<br><br>Nor are Defendants standing in the way of Louisiana enforcing its abortion laws against out-of state prescribers of mifepristone.<\/p>\n<\/blockquote>\n\n\n\n<p class=\"has-medium-font-size\">Yet, the Plaintiffs have made several\u00a0<a href=\"https:\/\/www.liveaction.org\/news\/destructive-sovereignty-louisiana-mail-order-abortion-pill\" target=\"_blank\" rel=\"noreferrer noopener\">important points\u00a0<\/a>describing the harm the 2023 REMS has on the state, on the taxpayers, and on women, including the following:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\">&#8220;Louisiana has suffered, and continues to suffer, a classic pocketbook injury from the 2023 REMS\u00a0<strong>in the form of hundreds of thousands of dollars in increased Medicaid costs attributable to mifepristone-induced abortions that have required emergency care<\/strong>\u00a0\u2014\u00a0<strong>costs that would not be incurred but for the 2023 REMS<\/strong>.&#8221;<\/li>\n\n\n\n<li class=\"has-medium-font-size\">&#8220;&#8230; Rosalie is not alone. Consider the well-known story of Margaret Carpenter, a New York doctor who mailed mifepristone to a Louisiana woman who forced the drug on her pregnant teenage daughter&#8230; The teen faced a medical emergency alone at home, called 911, and was rushed to the hospital in an ambulance after delivering a dead fetus&#8230;&#8221;<\/li>\n\n\n\n<li class=\"has-medium-font-size\"><strong>&#8220;[C]onsider data from the Louisiana Department of Health showing that over $92,000 in Medicaid dollars were paid for emergency room care and hospitalization resulting from just two mifepristone-induced abortions in 2025<\/strong>&#8230;&#8221;<\/li>\n<\/ul>\n\n\n\n<p class=\"has-medium-font-size\">The FDA claimed:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-medium-font-size\">Plaintiffs ask the Court to make the very sort of difficult scientific judgment about the 2023 REMS Modification that Congress entrusted to FDA while the agency itself is considering the same issues.<\/p>\n<\/blockquote>\n\n\n\n<p class=\"has-medium-font-size\">The agency suggested that if the Plaintiffs prevail before the FDA review is complete, &#8220;it could prompt the sponsors of mifepristone to file supplemental applications seeking modifications to the REMS.&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Commentary:<\/h2>\n\n\n\n<p class=\"has-medium-font-size\">In response, Senior Counsel and Director of the Center of Life Erik Baptist told Live Action News:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"has-medium-font-size\">\u201cWe are disappointed that the Trump administration is asking the court to pause our case and deny our clients immediate relief while the FDA takes years&nbsp;to study the known harms of abortion drugs&nbsp;and restore commonsense safeguards.<br><br>In its brief, the government does not defend the Biden FDA\u2019s reckless decision to allow mail-order abortions \u2014a decision that jeopardized women\u2019s safety and undermined the rule of law. That politics-driven decision by the Biden administration has cost the lives of&nbsp;untold numbers&nbsp;of unborn babies and caused real, ongoing, and documented harms to countless women whose trust the FDA betrayed. What\u2019s more, men can now order these drugs and coerce or trick women into taking them.<br><br>There is no reason to leave in place the concededly unlawful, dangerous&nbsp;removal of a vital protection&nbsp;for women while the FDA takes another year or more to conduct a study&nbsp;confirming what the FDA already knows\u2014that these are high-risk drugs&nbsp;and that mail-order abortions increase the risks to women.&nbsp;In this case, justice delayed truly is justice denied.<br><br>We are honored to stand with Louisiana and Rosalie Markezich in holding the FDA accountable and restoring the rule of law.\u201d<\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\">The Context:<\/h2>\n\n\n\n<p class=\"has-medium-font-size\">Three lawsuits involving six states are challenging the expansions of the abortion pill. The Alliance for Hippocratic Medicine (AHM) was the initial\u00a0<a href=\"https:\/\/www.supremecourt.gov\/opinions\/23pdf\/23-235_n7ip.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">challenge<\/a>; however, in 2024, the U.S. Supreme Court\u00a0<a href=\"https:\/\/www.liveaction.org\/news\/fact-check-supreme-court-abortion-pill-access\/\" target=\"_blank\" rel=\"noreferrer noopener\">ruled<\/a>\u00a0that the plaintiff doctors in AHM\u00a0<em>did\u00a0<\/em><a href=\"https:\/\/www.supremecourt.gov\/opinions\/23pdf\/23-235_n7ip.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><em>not have standing<\/em><\/a>\u00a0to sue, and they eventually dropped their challenge.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"has-medium-font-size\"><a href=\"https:\/\/www.liveaction.org\/news\/judge-rules-states-intervene-abortion-pill-lawsuit\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>January 2025<\/strong><\/a><strong>:<\/strong>\u00a0Judge Matthew Kacsmaryk\u00a0<a href=\"https:\/\/assets.aclu.org\/live\/uploads\/2023\/06\/177117394490.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">ruled<\/a>\u00a0the states of\u00a0<a href=\"https:\/\/litigationtracker.law.georgetown.edu\/wp-content\/uploads\/2024\/02\/Missouri_2025.08.22_MOTION-AND-MEMORANDUM-TO-INTERVENE.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Missouri, Kansas, and Idaho<\/a>\u00a0could intervene in AHM&#8217;s case and file a complaint in Amarillo, Texas.<\/li>\n\n\n\n<li class=\"has-medium-font-size\"><strong>May 2025<\/strong>: Trump\u2019s Department of Justice (DOJ)\u00a0<a href=\"https:\/\/www.liveaction.org\/news\/trump-doj-calls-dismissal-lawsuit-abortion-pill\" target=\"_blank\" rel=\"noreferrer noopener\">called<\/a>\u00a0for dismissal of the lawsuit.<\/li>\n\n\n\n<li class=\"has-medium-font-size\"><a href=\"https:\/\/www.liveaction.org\/news\/texas-and-florida-join-abortion-pill-lawsuit\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>August 2025<\/strong><\/a>: States of Texas and Florida\u00a0first\u00a0<a href=\"https:\/\/litigationtracker.law.georgetown.edu\/wp-content\/uploads\/2024\/02\/Missouri_2025.08.22_MOTION-AND-MEMORANDUM-TO-INTERVENE.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">petitioned the court<\/a>\u00a0to\u00a0<a href=\"https:\/\/www.liveaction.org\/news\/texas-and-florida-join-abortion-pill-lawsuit\" target=\"_blank\" rel=\"noreferrer noopener\">intervene<\/a>\u00a0\u2014 and one month later (<a href=\"https:\/\/www.liveaction.org\/news\/louisiana-woman-join-abortion-pill-lawsuit-fda\" target=\"_blank\" rel=\"noreferrer noopener\">September 2025<\/a>), Louisiana along with\u00a0<a href=\"https:\/\/www.liveaction.org\/news\/victim-coerced-mail-order-abortion-suing-fda\" target=\"_blank\" rel=\"noreferrer noopener\">Rosalie Markezich<\/a>\u00a0<a href=\"https:\/\/storage.courtlistener.com\/recap\/gov.uscourts.txnd.370067\/gov.uscourts.txnd.370067.264.2.pdf?ref=autonomynews.co\" target=\"_blank\" rel=\"noreferrer noopener\">filed a motion<\/a>\u00a0to do the same. Markezich claimed in her complaint that her boyfriend ordered abortion pills from a California provider and coerced her into taking the pills. Her baby died.<\/li>\n\n\n\n<li class=\"has-medium-font-size\"><strong>August 2025<\/strong>: Judge Kacsmaryk\u00a0<a href=\"https:\/\/litigationtracker.law.georgetown.edu\/wp-content\/uploads\/2024\/02\/State-of-Missouri_2025.09.30_ORDER-ON-MOTIONS-TO-DISMISS-THE-AMENDED-COMPLAINT-AND-INTERVENE.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">denied<\/a>\u00a0motions by Texas, Florida, and Louisiana and\u00a0<a href=\"https:\/\/missouriindependent.com\/2025\/10\/01\/federal-lawsuit-limit-access-abortion-pill-mifepristone-texas-missouri\/\" target=\"_blank\" rel=\"noreferrer noopener\">moved<\/a>\u00a0the venue to Missouri.<\/li>\n\n\n\n<li class=\"has-medium-font-size\"><strong>October 2025<\/strong>: Alliance Defending Freedom (ADF)\u00a0<a href=\"https:\/\/adflegal.org\/case\/the-state-of-louisiana-v-u-s-food-and-drug-administration\/#case-documents\" target=\"_blank\" rel=\"noreferrer noopener\">refiled<\/a>\u00a0the\u00a0<a href=\"https:\/\/adflegal.org\/wp-content\/uploads\/2025\/10\/louisiana-v-fda-2025-10-06-complaint.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">lawsuit<\/a><a href=\"https:\/\/adflegal.org\/wp-content\/uploads\/2025\/10\/louisiana-v-fda-2025-10-06-complaint.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">\u00a0<\/a>in\u00a0<em>State of Louisiana v. FDA<\/em>\u00a0(along with\u00a0<a href=\"https:\/\/adflegal.org\/wp-content\/uploads\/2025\/10\/louisiana-v-fda-2025-10-06-exhibit-92-rosalie-markezich-declaration.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Rosalie Markezich<\/a>) in the Western District of Louisiana, Lafayette Division.<\/li>\n\n\n\n<li class=\"has-medium-font-size\"><strong>December 9, 2025<\/strong>: A new\u00a0<a href=\"https:\/\/fingfx.thomsonreuters.com\/gfx\/legaldocs\/egvbbjdlxvq\/USA_ABORTION_MIFEPRISTONE_LAWSUIT_complaint.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">lawsuit<\/a>,\u00a0<em>State of Florida and the State of Texas v. FDA<\/em>,\u00a0was\u00a0<a href=\"https:\/\/www.liveaction.org\/news\/florida-texas-refile-lawsuit-challenging-abortion-pill\" target=\"_blank\" rel=\"noreferrer noopener\">filed<\/a>\u00a0in the Northern District of Texas, Wichita Falls Division.<\/li>\n\n\n\n<li class=\"has-medium-font-size\"><strong>December 17, 2025<\/strong>: Louisiana\u00a0<a href=\"https:\/\/www.liveaction.org\/assets\/1766071899-2025-12-17-lavfda-mpi-plaintiffs-memorandum-of-law-in-support-of-their-motion-for-preliminary-relief.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">filed<\/a>\u00a0for\u00a0<a href=\"https:\/\/www.liveaction.org\/news\/destructive-sovereignty-louisiana-mail-order-abortion-pill\" target=\"_blank\" rel=\"noreferrer noopener\">preliminary injunctive<\/a>\u00a0relief.<\/li>\n\n\n\n<li class=\"has-medium-font-size\"><strong>January 27, 2026:<\/strong>\u00a0FDA\u00a0<a href=\"https:\/\/www.courtlistener.com\/docket\/71544002\/louisiana-v-u-s-food-drug-administration\/\" target=\"_blank\" rel=\"noreferrer noopener\">filed a motion<\/a>\u00a0to stay the case.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Go Deeper:<\/h2>\n\n\n\n<p class=\"has-medium-font-size\">Live Action recently\u00a0<a href=\"https:\/\/www.liveaction.org\/news\/live-action-investigative-report-video-abortion-pill\">rele<\/a><a href=\"https:\/\/www.liveaction.org\/news\/live-action-investigative-report-video-abortion-pill\" target=\"_blank\" rel=\"noreferrer noopener\">a<\/a><a href=\"https:\/\/www.liveaction.org\/news\/live-action-investigative-report-video-abortion-pill\">sed<\/a>\u00a0a<a href=\"https:\/\/www.liveaction.org\/assets\/1769045841-la26-the-state-of-chemical-abortion-01-20-26-updated-1.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">\u00a0white paper<\/a>\u00a0documenting the history and horrors of the abortion pill, including Big Abortion&#8217;s deliberate and lengthy scheme to hide adverse events from the FDA.<\/p>\n\n\n\n<p style=\"font-size:18px\"><em>Editor&#8217;s Note, 1\/28\/26: A quote from ADF counsel has been added to this post since original publication.<\/em><\/p>\n\n\n\n<p style=\"font-size:18px\"><strong><em>Carole Novielli is an author at LiveAction News with over thirty years of research experience on abortion, Planned Parenthood and eugenics.<\/em><\/strong><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By: Carole Novielli, originally published January 28, 2026, LiveAction.org he Food and Drug Administration (FDA) under the Trump administration has petitioned a federal court to&nbsp;pause&nbsp;the state of Louisiana&#8217;s abortion pill lawsuit, which is seeking a review of the 2023 safety regulations on the drug. The troubling motion comes just days after President Donald Trump and&hellip;<\/p>\n","protected":false},"author":2,"featured_media":35680,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-35677","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Trump FDA seeks pause on abortion pill lawsuit while it reviews drug&#039;s risks - Cincinnati Right to Life<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trump FDA seeks pause on abortion pill lawsuit while it reviews drug&#039;s risks - Cincinnati Right to Life\" \/>\n<meta property=\"og:description\" content=\"By: Carole Novielli, originally published January 28, 2026, LiveAction.org he Food and Drug Administration (FDA) under the Trump administration has petitioned a federal court to&nbsp;pause&nbsp;the state of Louisiana&#8217;s abortion pill lawsuit, which is seeking a review of the 2023 safety regulations on the drug. The troubling motion comes just days after President Donald Trump and&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/\" \/>\n<meta property=\"og:site_name\" content=\"Cincinnati Right to Life\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T18:45:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T18:45:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/FDA-seeks-pause-on-abortion-pill.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Melanie Wade\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Melanie Wade\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/\",\"url\":\"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/\",\"name\":\"Trump FDA seeks pause on abortion pill lawsuit while it reviews drug's risks - Cincinnati Right to Life\",\"isPartOf\":{\"@id\":\"https:\/\/cincinnatirighttolife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/FDA-seeks-pause-on-abortion-pill.png\",\"datePublished\":\"2026-01-30T18:45:50+00:00\",\"dateModified\":\"2026-01-30T18:45:51+00:00\",\"author\":{\"@id\":\"https:\/\/cincinnatirighttolife.org\/#\/schema\/person\/9a5fe1347253fa134f21cdb919caf789\"},\"breadcrumb\":{\"@id\":\"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/#primaryimage\",\"url\":\"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/FDA-seeks-pause-on-abortion-pill.png\",\"contentUrl\":\"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/FDA-seeks-pause-on-abortion-pill.png\",\"width\":1200,\"height\":600},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cincinnatirighttolife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trump FDA seeks pause on abortion pill lawsuit while it reviews drug&#8217;s risks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cincinnatirighttolife.org\/#website\",\"url\":\"https:\/\/cincinnatirighttolife.org\/\",\"name\":\"Cincinnati Right to Life\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cincinnatirighttolife.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cincinnatirighttolife.org\/#\/schema\/person\/9a5fe1347253fa134f21cdb919caf789\",\"name\":\"Melanie Wade\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cincinnatirighttolife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7ec3fd7a1977f4be962597ccc3e12001?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7ec3fd7a1977f4be962597ccc3e12001?s=96&d=mm&r=g\",\"caption\":\"Melanie Wade\"},\"url\":\"https:\/\/cincinnatirighttolife.org\/author\/mwade\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trump FDA seeks pause on abortion pill lawsuit while it reviews drug's risks - Cincinnati Right to Life","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/","og_locale":"en_US","og_type":"article","og_title":"Trump FDA seeks pause on abortion pill lawsuit while it reviews drug's risks - Cincinnati Right to Life","og_description":"By: Carole Novielli, originally published January 28, 2026, LiveAction.org he Food and Drug Administration (FDA) under the Trump administration has petitioned a federal court to&nbsp;pause&nbsp;the state of Louisiana&#8217;s abortion pill lawsuit, which is seeking a review of the 2023 safety regulations on the drug. The troubling motion comes just days after President Donald Trump and&hellip;","og_url":"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/","og_site_name":"Cincinnati Right to Life","article_published_time":"2026-01-30T18:45:50+00:00","article_modified_time":"2026-01-30T18:45:51+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/FDA-seeks-pause-on-abortion-pill.png","type":"image\/png"}],"author":"Melanie Wade","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Melanie Wade","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/","url":"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/","name":"Trump FDA seeks pause on abortion pill lawsuit while it reviews drug's risks - Cincinnati Right to Life","isPartOf":{"@id":"https:\/\/cincinnatirighttolife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/#primaryimage"},"image":{"@id":"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/#primaryimage"},"thumbnailUrl":"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/FDA-seeks-pause-on-abortion-pill.png","datePublished":"2026-01-30T18:45:50+00:00","dateModified":"2026-01-30T18:45:51+00:00","author":{"@id":"https:\/\/cincinnatirighttolife.org\/#\/schema\/person\/9a5fe1347253fa134f21cdb919caf789"},"breadcrumb":{"@id":"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/#primaryimage","url":"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/FDA-seeks-pause-on-abortion-pill.png","contentUrl":"https:\/\/cincinnatirighttolife.org\/wp-content\/uploads\/2026\/01\/FDA-seeks-pause-on-abortion-pill.png","width":1200,"height":600},{"@type":"BreadcrumbList","@id":"https:\/\/cincinnatirighttolife.org\/trump-fda-seeks-pause-on-abortion-pill-lawsuit-while-it-reviews-drugs-risks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cincinnatirighttolife.org\/"},{"@type":"ListItem","position":2,"name":"Trump FDA seeks pause on abortion pill lawsuit while it reviews drug&#8217;s risks"}]},{"@type":"WebSite","@id":"https:\/\/cincinnatirighttolife.org\/#website","url":"https:\/\/cincinnatirighttolife.org\/","name":"Cincinnati Right to Life","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cincinnatirighttolife.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cincinnatirighttolife.org\/#\/schema\/person\/9a5fe1347253fa134f21cdb919caf789","name":"Melanie Wade","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cincinnatirighttolife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7ec3fd7a1977f4be962597ccc3e12001?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7ec3fd7a1977f4be962597ccc3e12001?s=96&d=mm&r=g","caption":"Melanie Wade"},"url":"https:\/\/cincinnatirighttolife.org\/author\/mwade\/"}]}},"_links":{"self":[{"href":"https:\/\/cincinnatirighttolife.org\/wp-json\/wp\/v2\/posts\/35677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cincinnatirighttolife.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cincinnatirighttolife.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cincinnatirighttolife.org\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cincinnatirighttolife.org\/wp-json\/wp\/v2\/comments?post=35677"}],"version-history":[{"count":1,"href":"https:\/\/cincinnatirighttolife.org\/wp-json\/wp\/v2\/posts\/35677\/revisions"}],"predecessor-version":[{"id":35681,"href":"https:\/\/cincinnatirighttolife.org\/wp-json\/wp\/v2\/posts\/35677\/revisions\/35681"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cincinnatirighttolife.org\/wp-json\/wp\/v2\/media\/35680"}],"wp:attachment":[{"href":"https:\/\/cincinnatirighttolife.org\/wp-json\/wp\/v2\/media?parent=35677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cincinnatirighttolife.org\/wp-json\/wp\/v2\/categories?post=35677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cincinnatirighttolife.org\/wp-json\/wp\/v2\/tags?post=35677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}